MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Business/Financial News / Moximed closes $50m Series C

Moximed closes $50m Series C

March 16, 2017 By Fink Densford Leave a Comment

Moximed

California orthopedic device developer Moximed said today it raised $50 million in a Series C round of financing.

The round was joined by newly invested Advent Life Sciences and Future fund and existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners and Vertex Healthcare.

“This financing round is timely, as we are completing the primary endpoint follow-up for our FDA pivotal study this month. We expect this investment to fully fund the company through FDA approval and early US commercialization of our products. There is a massive demand for new treatment options by patients who want to maintain an active lifestyle until they are ready for a knee replacement. The tremendous patient interest and surgeon enthusiasm we are witnessing in our current Atlas IDE study is validating our effort to address this clinical need,” CEO Kevin Sidow said in a prepared statement.

As part of the funding round, Advent Life Sciences general partner Dr. Shahzad Malik and GBS Venture Partners managing director Brigitte Smith will join the company’s board of directors.

“Patients between the ages of 35 and 65 years old represent the fastest growing segment of the knee OA population. These patients are often considered too young for traditional joint replacement and are desperate for a treatment alternative. We are excited to support Moximed’s effort to address this opportunity,” Malik said in a press release.

Last November, Moximed said it enrolled the 1st patient in an FDA approved investigational device exemption trial of its next-gen Atlas unicompartmental unloading knee implant.

The Atlas is designed to treat osteoarthritis knee joint pain in patients ages 35 to 65 whose condition has not degenerated enough to require arthroplasty. The device is a joint unloader placed along the knee to absorb excess load and buy time.

The cylindrical shock absorber component is about as long as a standard house key and has the diameter of a pencil, and the bases that attach to the bone have a footprint a bit larger than a quarter. Once the osteoarthritis becomes too severe, Atlas can be taken out to make room for a full knee replacement as needed.

Filed Under: Business/Financial News, Orthopedics Tagged With: Moximed

In case you missed it

  • Medtronic faces patent lawsuit over CoreValve tech
  • Orpyx launches sensory insoles with patient monitoring
  • Ortho devicemakers Hensler and Tobra face off in patent lawsuit
  • House bill asks CMS to cover breakthrough devices for Medicare patients
  • Empirical Spine completes enrollment in LimiFlex pivotal trial
  • MolecuLight wins FDA clearance for handheld imaging device
  • Medical device tax will cost 20,000 jobs, report says
  • W.L. Gore officials think they can spur insulin delivery system innovation
  • EPA moves closer to stricter regulations on medtech ethylene oxide sterilization
  • 3DBio Therapeutics wins FDA rare pediatric disease designation for outer ear reconstruction
  • CryoLife wins CE Mark for E-nya thoracic stent graft
  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS